1. Home
  2. ECX vs PRTC Comparison

ECX vs PRTC Comparison

Compare ECX & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ECARX Holdings Inc. Ordinary shares

ECX

ECARX Holdings Inc. Ordinary shares

HOLD

Current Price

$1.77

Market Cap

560.1M

Sector

Technology

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

N/A

Current Price

$16.80

Market Cap

464.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ECX
PRTC
Founded
2017
2015
Country
China
United States
Employees
1918
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
560.1M
464.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ECX
PRTC
Price
$1.77
$16.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.1M
3.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$825.35
N/A
Revenue Next Year
$35.50
N/A
P/E Ratio
N/A
$8.09
Revenue Growth
N/A
N/A
52 Week Low
$0.76
$13.30
52 Week High
$3.25
$20.00

Technical Indicators

Market Signals
Indicator
ECX
PRTC
Relative Strength Index (RSI) 52.69 42.50
Support Level $1.57 $16.60
Resistance Level $1.77 $18.10
Average True Range (ATR) 0.16 0.43
MACD 0.02 -0.11
Stochastic Oscillator 76.18 19.02

Price Performance

Historical Comparison
ECX
PRTC

About ECX ECARX Holdings Inc. Ordinary shares

ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: